SARS-CoV-2 |
Spike protein |
Au NPs |
SARS-COV-2, S1 spike protein |
2,3′-sialyl lactose-BSA |
– |
5 μg |
[45] |
SARS-CoV-2 |
Anti-SARS-CoV-2 IgM |
Au NPs |
SARS-CoV-2 NP |
Anti-mouse IgG |
100% |
– |
[46] |
SARS-CoV-2 |
RNA |
Au NPs |
Anti-FITC Ab |
Biotin |
100% |
– |
[47] |
SARS-CoV-2 |
Nucleoprotein Ag |
Cellulose nanobead |
Nucleoprotein Ag |
Anti-human IgG antibodies |
– |
2 ng |
[48] |
SARS CoV-2 |
Anti-SARS-CoV-2 IgM- IgG - IgM |
Au-NPs |
Protein A & nucleocapsid proteins |
Avidin |
94.6% |
– |
[49] |
SARS CoV-2 |
Anti-SARS-CoV-2 IgA |
Au-NPs |
Nucleocapsid antigen |
staphylococcal protein A |
– |
– |
[50] |
SARS CoV-2 |
Anti-SARS-CoV-2 IgG |
Au-NPs |
SARS CoV-2 |
Anti-mouse IgG |
69.1% |
– |
[51] |
SARS CoV-2 |
Nucleoprotein and spike protein |
Au-NPs |
Mouse anti-human IgG and anti-human IgM |
mouse anti-tylosin antibody |
96% |
– |
[52] |
IAV |
Nucleoprotein Ag |
Au/Pt NPs conjugated with anti-Influenza A NP |
Anti-Influenza A Ab |
Anti-mouse IgG |
94% |
– |
[53] |
IAV |
Nucleoproteins |
Ca-coated UC NPs conjugated with anti-AIV NP Ab |
Anti-AIV NP Ab |
GAM IgG |
– |
103.5 EID50/mL |
[54] |
Tamiflu-resistant Influenza virus |
Antiviral neuraminidase |
Au NPs conjugated with OHT |
Anti-AIV nucleoproteins (NP) |
Tamiflu resistant NPs |
– |
5 × 102 PFU |
[55] |
IAV - IBV |
IAV and IBV antigens |
Europium |
Monoclonal anti-influenza A and monoclonal anti-influenza B mouse IgG |
polyclonal mouse IgG |
68.9% |
– |
[56] |
HIV, HCV, HAV |
Antiviral Abs |
Au NPs conjugated with protein A, BSA and proteinticles |
Specific proteinticles |
GAH Abs |
100% |
– |
[57] |
HIV |
HIV-1 DNA |
Au NPs conjugated with Raman reporter MGITC and DNA detection |
Capture DNAs |
Control DNAs |
– |
0.24 pg/mL |
[58] |
HIV |
HIV DNA |
QDs conjugated with hairpin DNA |
Test-DNA |
Control-DNA |
– |
0.76 pM |
[59] |
HIV, HCV, HBV |
HIV, HCV, HBV Abs |
QD nanobeads |
HIV-1/2, HCV, HBV, and HBs antigens |
GAM IgG |
88.33–93.42% |
– |
[60] |
HBV |
HBV DNA |
detProbe-Au-ssDNA |
T-DNA |
C-DNA |
– |
102 IU/mL |
[61] |
HBV |
HBs Ag |
UC NPs |
AntiHBsAg mAb |
RAM IgG |
95.4%, |
– |
[62] |
DENV |
Anti-Dengue Ab |
DYlight-800 |
Recombinant Dengue type 1 envelope |
GAH IgG |
95% |
– |
[63] |
DENV |
Dengue NS1 |
Magnetic beads |
mAbs |
GAM Ab |
– |
0.1 ng/ml |
[64] |
DENV |
Dengue-1 RNA |
Au NPs |
dDNA |
cDNA |
– |
1.2 × 104 pfu/mL |
[65] |
HPV |
HPV16 E7 and HPV18 L1 |
SA-DNPs |
Anti-FITC and anti-DIG |
Biotin-BSA |
– |
5 × 105 copies |
[66] |
TORCH pathogens |
IgM Abs |
Au/hemin@MOF (metal organic framework) |
Torch Ab |
GAM IgG Ab |
100% |
– |
[67] |
EV |
EV glycoprotein |
RNs@Au |
Anti-Ebola glycoprotein Ab |
Anti-human Ab |
– |
2 ng/mL |
[68] |
EV |
EV glycoprotein |
AuNP |
EE8 Ab |
Anti-mouse immunoglobulin |
85.7% |
2.2 x 104 genome copies/ml |
[69] |
EV |
EV glycoprotein |
AuNP |
mAb 1HK7 - mAb 2HK1 |
Goat anti-mouse Ig |
|
0.23–0.37 ng/mL |
[70] |
SFTSV |
SFTSV NP |
Au NPs |
mAbs |
GAM IgG |
– |
1 ng/mL |
[71] |